End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?
Cathérine Dekeyser, De Pue Annelien, Sieben Anne, Luc Algoed, Van Hijfte Liesbeth, Sarah Gerlo, Guy Laureys
Topics & Concepts
NatalizumabMedicineMultiple sclerosisImmunologyInternal medicineMultiple Sclerosis Research StudiesPolyomavirus and related diseasesCancer survivorship and care